Neuronetics, Inc. (NASDAQ: STIM) Stock Competitors & Peer Comparison
See STIM's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for STIM and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| STIM | $2.38 | +5.78% | 165.6M | -4.41 | -$0.54 | N/A |
| ABT | $107.81 | -0.14% | 186.5B | 20.69 | $5.21 | +2.31% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $339.03 | +0.47% | 130B | 25.32 | $13.39 | +1.03% |
| MDT | $87.16 | +1.44% | 111.6B | 15.76 | $5.53 | +3.29% |
| BSX | $49.31 | +0.02% | 73.3B | 15.91 | $3.10 | N/A |
| EW | $89.72 | +0.45% | 51.7B | 33.23 | $2.70 | N/A |
| DXCM | $84.75 | +2.08% | 32B | 36.37 | $2.33 | N/A |
| RMD | $211.94 | -5.06% | 30.7B | 19.68 | $10.77 | +1.15% |
| PHG | $26.73 | +1.52% | 26.1B | 15.28 | $1.75 | +3.70% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
STIM vs ABT Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, ABT has a market cap of 186.5B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while ABT trades at $107.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas ABT's P/E ratio is 20.69. In terms of profitability, STIM's ROE is -1.65%, compared to ABT's ROE of +0.11%. Regarding short-term risk, STIM is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for STIM.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
STIM vs BSX-PA Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, STIM's ROE is -1.65%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, STIM is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for STIM.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
STIM vs SYK Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, SYK has a market cap of 130B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while SYK trades at $339.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas SYK's P/E ratio is 25.32. In terms of profitability, STIM's ROE is -1.65%, compared to SYK's ROE of +0.16%. Regarding short-term risk, STIM is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for STIM.Check SYK's competition here
Medtronic plc (NYSE: MDT)
STIM vs MDT Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, MDT has a market cap of 111.6B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while MDT trades at $87.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas MDT's P/E ratio is 15.76. In terms of profitability, STIM's ROE is -1.65%, compared to MDT's ROE of +0.10%. Regarding short-term risk, STIM is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for STIM.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
STIM vs BSX Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, BSX has a market cap of 73.3B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while BSX trades at $49.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas BSX's P/E ratio is 15.91. In terms of profitability, STIM's ROE is -1.65%, compared to BSX's ROE of +0.15%. Regarding short-term risk, STIM is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for STIM.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
STIM vs EW Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, EW has a market cap of 51.7B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while EW trades at $89.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas EW's P/E ratio is 33.23. In terms of profitability, STIM's ROE is -1.65%, compared to EW's ROE of +0.10%. Regarding short-term risk, STIM is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for STIM.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
STIM vs DXCM Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, DXCM has a market cap of 32B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while DXCM trades at $84.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas DXCM's P/E ratio is 36.37. In terms of profitability, STIM's ROE is -1.65%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, STIM is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for STIM.Check DXCM's competition here
ResMed Inc. (NYSE: RMD)
STIM vs RMD Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, RMD has a market cap of 30.7B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while RMD trades at $211.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas RMD's P/E ratio is 19.68. In terms of profitability, STIM's ROE is -1.65%, compared to RMD's ROE of +0.24%. Regarding short-term risk, STIM is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for STIM.Check RMD's competition here
Koninklijke Philips N.V. (NYSE: PHG)
STIM vs PHG Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, PHG has a market cap of 26.1B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while PHG trades at $26.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas PHG's P/E ratio is 15.28. In terms of profitability, STIM's ROE is -1.65%, compared to PHG's ROE of +0.10%. Regarding short-term risk, STIM is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for STIM.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
STIM vs ZBH Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, ZBH has a market cap of 18.7B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while ZBH trades at $96.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas ZBH's P/E ratio is 11.38. In terms of profitability, STIM's ROE is -1.65%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, STIM is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for STIM.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
STIM vs ABMD Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas ABMD's P/E ratio is 65.36. In terms of profitability, STIM's ROE is -1.65%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, STIM is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for STIM.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
STIM vs PEN Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while PEN trades at $324.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas PEN's P/E ratio is 84.77. In terms of profitability, STIM's ROE is -1.65%, compared to PEN's ROE of +0.11%. Regarding short-term risk, STIM is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for STIM.Check PEN's competition here
Smith & Nephew plc (NYSE: SNN)
STIM vs SNN Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, SNN has a market cap of 12.6B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while SNN trades at $30.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas SNN's P/E ratio is 14.16. In terms of profitability, STIM's ROE is -1.65%, compared to SNN's ROE of +0.12%. Regarding short-term risk, STIM is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for STIM.Check SNN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
STIM vs SWAV Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas SWAV's P/E ratio is 78.76. In terms of profitability, STIM's ROE is -1.65%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, STIM is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for STIM.Check SWAV's competition here
Align Technology, Inc. (NASDAQ: ALGN)
STIM vs ALGN Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while ALGN trades at $173.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas ALGN's P/E ratio is 15.83. In terms of profitability, STIM's ROE is -1.65%, compared to ALGN's ROE of +0.14%. Regarding short-term risk, STIM is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for STIM.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
STIM vs GMED Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, GMED has a market cap of 11.1B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while GMED trades at $82.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas GMED's P/E ratio is 18.56. In terms of profitability, STIM's ROE is -1.65%, compared to GMED's ROE of +0.12%. Regarding short-term risk, STIM is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for STIM.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
STIM vs GKOS Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, GKOS has a market cap of 10.6B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while GKOS trades at $180.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas GKOS's P/E ratio is -209.45. In terms of profitability, STIM's ROE is -1.65%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, STIM is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for STIM.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
STIM vs PODD Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, PODD has a market cap of 9.8B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while PODD trades at $141.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas PODD's P/E ratio is 24.05. In terms of profitability, STIM's ROE is -1.65%, compared to PODD's ROE of +0.27%. Regarding short-term risk, STIM is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for STIM.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
STIM vs BIO-B Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, BIO-B has a market cap of 9.5B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while BIO-B trades at $349.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas BIO-B's P/E ratio is 103.54. In terms of profitability, STIM's ROE is -1.65%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, STIM is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for STIM.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
STIM vs BIO Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, BIO has a market cap of 9.5B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while BIO trades at $352.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas BIO's P/E ratio is 38.00. In terms of profitability, STIM's ROE is -1.65%, compared to BIO's ROE of +0.03%. Regarding short-term risk, STIM is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for STIM.Check BIO's competition here
Masimo Corporation (NASDAQ: MASI)
STIM vs MASI Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas MASI's P/E ratio is 44.43. In terms of profitability, STIM's ROE is -1.65%, compared to MASI's ROE of +0.09%. Regarding short-term risk, STIM is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for STIM.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
STIM vs BRKR Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, BRKR has a market cap of 8.1B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while BRKR trades at $53.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas BRKR's P/E ratio is 26.84. In terms of profitability, STIM's ROE is -1.65%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, STIM is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for STIM.Check BRKR's competition here
Inari Medical, Inc. (NASDAQ: NARI)
STIM vs NARI Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas NARI's P/E ratio is -59.24. In terms of profitability, STIM's ROE is -1.65%, compared to NARI's ROE of -0.00%. Regarding short-term risk, STIM is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for STIM.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
STIM vs ITGR Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while ITGR trades at $125.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas ITGR's P/E ratio is 19.72. In terms of profitability, STIM's ROE is -1.65%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, STIM is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for STIM.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
STIM vs IRTC Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, IRTC has a market cap of 4.2B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while IRTC trades at $127.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas IRTC's P/E ratio is -199.75. In terms of profitability, STIM's ROE is -1.65%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, STIM is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for STIM.Check IRTC's competition here
LivaNova PLC (NASDAQ: LIVN)
STIM vs LIVN Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while LIVN trades at $76.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas LIVN's P/E ratio is 18.10. In terms of profitability, STIM's ROE is -1.65%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, STIM is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for STIM.Check LIVN's competition here
Haemonetics Corporation (NYSE: HAE)
STIM vs HAE Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, HAE has a market cap of 4B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while HAE trades at $87.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas HAE's P/E ratio is 17.54. In terms of profitability, STIM's ROE is -1.65%, compared to HAE's ROE of +0.11%. Regarding short-term risk, STIM is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for STIM.Check HAE's competition here
Axonics, Inc. (NASDAQ: AXNX)
STIM vs AXNX Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas AXNX's P/E ratio is -709.80. In terms of profitability, STIM's ROE is -1.65%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, STIM is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for STIM.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
STIM vs TMDX Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while TMDX trades at $83.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas TMDX's P/E ratio is 42.58. In terms of profitability, STIM's ROE is -1.65%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, STIM is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for STIM.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
STIM vs AXGN Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, AXGN has a market cap of 2.5B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while AXGN trades at $46.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas AXGN's P/E ratio is 122.18. In terms of profitability, STIM's ROE is -1.65%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, STIM is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for STIM.Check AXGN's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
STIM vs UFPT Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, UFPT has a market cap of 2.4B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while UFPT trades at $314.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas UFPT's P/E ratio is 32.07. In terms of profitability, STIM's ROE is -1.65%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, STIM is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for STIM.Check UFPT's competition here
Butterfly Network, Inc. (NYSE: BFLY)
STIM vs BFLY Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, BFLY has a market cap of 2.3B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while BFLY trades at $8.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas BFLY's P/E ratio is -36.77. In terms of profitability, STIM's ROE is -1.65%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, STIM is more volatile compared to BFLY. This indicates higher risk in terms of short-term price fluctuations for STIM.Check BFLY's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
STIM vs ESTA Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, ESTA has a market cap of 2.3B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while ESTA trades at $77.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas ESTA's P/E ratio is -61.44. In terms of profitability, STIM's ROE is -1.65%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, STIM is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for STIM.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
STIM vs NUVA Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas NUVA's P/E ratio is 75.00. In terms of profitability, STIM's ROE is -1.65%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, STIM is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for STIM.Check NUVA's competition here
Novocure Ltd (NASDAQ: NVCR)
STIM vs NVCR Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while NVCR trades at $16.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas NVCR's P/E ratio is -10.71. In terms of profitability, STIM's ROE is -1.65%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, STIM is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for STIM.Check NVCR's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
STIM vs INSP Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while INSP trades at $60.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas INSP's P/E ratio is 26.51. In terms of profitability, STIM's ROE is -1.65%, compared to INSP's ROE of +0.18%. Regarding short-term risk, STIM is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for STIM.Check INSP's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
STIM vs TNDM Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, TNDM has a market cap of 1.5B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while TNDM trades at $22.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas TNDM's P/E ratio is -20.35. In terms of profitability, STIM's ROE is -1.65%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, STIM is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for STIM.Check TNDM's competition here
Enovis Corporation (NYSE: ENOV)
STIM vs ENOV Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while ENOV trades at $26.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas ENOV's P/E ratio is 7.62. In terms of profitability, STIM's ROE is -1.65%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, STIM is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for STIM.Check ENOV's competition here
CONMED Corporation (NYSE: CNMD)
STIM vs CNMD Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while CNMD trades at $49.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas CNMD's P/E ratio is 10.78. In terms of profitability, STIM's ROE is -1.65%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, STIM is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for STIM.Check CNMD's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
STIM vs ATEC Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while ATEC trades at $9.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas ATEC's P/E ratio is -155.17. In terms of profitability, STIM's ROE is -1.65%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, STIM is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for STIM.Check ATEC's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
STIM vs IART Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while IART trades at $17.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas IART's P/E ratio is 7.31. In terms of profitability, STIM's ROE is -1.65%, compared to IART's ROE of -0.01%. Regarding short-term risk, STIM is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for STIM.Check IART's competition here
Artivion, Inc. (NYSE: AORT)
STIM vs AORT Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while AORT trades at $27.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas AORT's P/E ratio is 45.28. In terms of profitability, STIM's ROE is -1.65%, compared to AORT's ROE of -0.01%. Regarding short-term risk, STIM is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for STIM.Check AORT's competition here
Heska Corporation (NASDAQ: HSKA)
STIM vs HSKA Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas HSKA's P/E ratio is -62.49. In terms of profitability, STIM's ROE is -1.65%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, STIM is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for STIM.Check HSKA's competition here
IRadimed Corporation (NASDAQ: IRMD)
STIM vs IRMD Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while IRMD trades at $92.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas IRMD's P/E ratio is 46.48. In terms of profitability, STIM's ROE is -1.65%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, STIM is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for STIM.Check IRMD's competition here
Avanos Medical, Inc. (NYSE: AVNS)
STIM vs AVNS Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas AVNS's P/E ratio is 27.77. In terms of profitability, STIM's ROE is -1.65%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, STIM is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for STIM.Check AVNS's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
STIM vs PRCT Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while PRCT trades at $20.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas PRCT's P/E ratio is -10.52. In terms of profitability, STIM's ROE is -1.65%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, STIM is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for STIM.Check PRCT's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
STIM vs SILK Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas SILK's P/E ratio is -18.96. In terms of profitability, STIM's ROE is -1.65%, compared to SILK's ROE of -0.35%. Regarding short-term risk, STIM is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for STIM.Check SILK's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
STIM vs LMRI Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while LMRI trades at $11.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas LMRI's P/E ratio is -22.53. In terms of profitability, STIM's ROE is -1.65%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, STIM is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for STIM.Check LMRI's competition here
Paragon 28, Inc. (NYSE: FNA)
STIM vs FNA Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas FNA's P/E ratio is -19.83. In terms of profitability, STIM's ROE is -1.65%, compared to FNA's ROE of -0.35%. Regarding short-term risk, STIM is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for STIM.Check FNA's competition here
Bioventus Inc. (NASDAQ: BVS)
STIM vs BVS Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, BVS has a market cap of 956.9M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while BVS trades at $14.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas BVS's P/E ratio is 18.59. In terms of profitability, STIM's ROE is -1.65%, compared to BVS's ROE of +0.28%. Regarding short-term risk, STIM is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for STIM.Check BVS's competition here
InMode Ltd. (NASDAQ: INMD)
STIM vs INMD Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, INMD has a market cap of 880M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while INMD trades at $15.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas INMD's P/E ratio is 10.63. In terms of profitability, STIM's ROE is -1.65%, compared to INMD's ROE of +0.13%. Regarding short-term risk, STIM is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for STIM.Check INMD's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
STIM vs AVR Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, AVR has a market cap of 866.3M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while AVR trades at $8.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas AVR's P/E ratio is -4.00. In terms of profitability, STIM's ROE is -1.65%, compared to AVR's ROE of -1.24%. Regarding short-term risk, STIM is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for STIM.Check AVR's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
STIM vs CSII Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas CSII's P/E ratio is -20.83. In terms of profitability, STIM's ROE is -1.65%, compared to CSII's ROE of -0.14%. Regarding short-term risk, STIM is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for STIM.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
STIM vs SIBN Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, SIBN has a market cap of 825.3M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while SIBN trades at $18.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas SIBN's P/E ratio is -54.74. In terms of profitability, STIM's ROE is -1.65%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, STIM is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for STIM.Check SIBN's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
STIM vs AHCO Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, AHCO has a market cap of 774.1M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while AHCO trades at $5.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas AHCO's P/E ratio is 11.61. In terms of profitability, STIM's ROE is -1.65%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, STIM is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for STIM.Check AHCO's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
STIM vs SSII Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, SSII has a market cap of 754.5M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while SSII trades at $3.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas SSII's P/E ratio is -73.53. In terms of profitability, STIM's ROE is -1.65%, compared to SSII's ROE of -0.23%. Regarding short-term risk, STIM is more volatile compared to SSII. This indicates higher risk in terms of short-term price fluctuations for STIM.Check SSII's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
STIM vs BBNX Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, BBNX has a market cap of 715.3M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while BBNX trades at $15.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas BBNX's P/E ratio is -10.53. In terms of profitability, STIM's ROE is -1.65%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, STIM is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for STIM.Check BBNX's competition here
CeriBell, Inc. (NASDAQ: CBLL)
STIM vs CBLL Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, CBLL has a market cap of 713.7M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while CBLL trades at $18.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas CBLL's P/E ratio is -11.54. In terms of profitability, STIM's ROE is -1.65%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, STIM is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for STIM.Check CBLL's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
STIM vs TCMD Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, TCMD has a market cap of 665.4M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while TCMD trades at $29.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas TCMD's P/E ratio is 33.52. In terms of profitability, STIM's ROE is -1.65%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, STIM is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for STIM.Check TCMD's competition here
Surmodics, Inc. (NASDAQ: SRDX)
STIM vs SRDX Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas SRDX's P/E ratio is -34.66. In terms of profitability, STIM's ROE is -1.65%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, STIM is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for STIM.Check SRDX's competition here
BrainsWay Ltd. (NASDAQ: BWAY)
STIM vs BWAY Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, BWAY has a market cap of 608M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while BWAY trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas BWAY's P/E ratio is 39.38. In terms of profitability, STIM's ROE is -1.65%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, STIM is more volatile compared to BWAY. This indicates higher risk in terms of short-term price fluctuations for STIM.Check BWAY's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
STIM vs KIDS Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, KIDS has a market cap of 584.8M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while KIDS trades at $22.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas KIDS's P/E ratio is -19.30. In terms of profitability, STIM's ROE is -1.65%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, STIM is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for STIM.Check KIDS's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
STIM vs APEN Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas APEN's P/E ratio is -9.43. In terms of profitability, STIM's ROE is -1.65%, compared to APEN's ROE of -0.85%. Regarding short-term risk, STIM is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for STIM.Check APEN's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
STIM vs CTKB Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, CTKB has a market cap of 542.4M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while CTKB trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas CTKB's P/E ratio is -22.25. In terms of profitability, STIM's ROE is -1.65%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, STIM is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for STIM.Check CTKB's competition here
ZimVie Inc. (NASDAQ: ZIMV)
STIM vs ZIMV Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, STIM's ROE is -1.65%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, STIM is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for STIM.Check ZIMV's competition here
Varex Imaging Corporation (NASDAQ: VREX)
STIM vs VREX Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, VREX has a market cap of 522.5M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while VREX trades at $12.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas VREX's P/E ratio is 13.06. In terms of profitability, STIM's ROE is -1.65%, compared to VREX's ROE of -0.18%. Regarding short-term risk, STIM is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for STIM.Check VREX's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
STIM vs DCTH Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, DCTH has a market cap of 521.6M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while DCTH trades at $15.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas DCTH's P/E ratio is 1511.00. In terms of profitability, STIM's ROE is -1.65%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, STIM is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for STIM.Check DCTH's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
STIM vs NPCE Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, NPCE has a market cap of 505.6M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while NPCE trades at $14.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas NPCE's P/E ratio is -25.57. In terms of profitability, STIM's ROE is -1.65%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, STIM is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for STIM.Check NPCE's competition here
Cerus Corporation (NASDAQ: CERS)
STIM vs CERS Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, CERS has a market cap of 473.6M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while CERS trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas CERS's P/E ratio is -46.91. In terms of profitability, STIM's ROE is -1.65%, compared to CERS's ROE of -0.10%. Regarding short-term risk, STIM is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for STIM.Check CERS's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
STIM vs CLPT Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, CLPT has a market cap of 426.2M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while CLPT trades at $14.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas CLPT's P/E ratio is -12.04. In terms of profitability, STIM's ROE is -1.65%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, STIM is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for STIM.Check CLPT's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
STIM vs OFIX Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, OFIX has a market cap of 415.5M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while OFIX trades at $10.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas OFIX's P/E ratio is -13.43. In terms of profitability, STIM's ROE is -1.65%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, STIM is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for STIM.Check OFIX's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
STIM vs SGHT Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, SGHT has a market cap of 406.4M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while SGHT trades at $7.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas SGHT's P/E ratio is -13.34. In terms of profitability, STIM's ROE is -1.65%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, STIM is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for STIM.Check SGHT's competition here
Carlsmed, Inc. (NASDAQ: CARL)
STIM vs CARL Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, CARL has a market cap of 375.7M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while CARL trades at $13.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas CARL's P/E ratio is -9.66. In terms of profitability, STIM's ROE is -1.65%, compared to CARL's ROE of -0.38%. Regarding short-term risk, STIM is more volatile compared to CARL. This indicates higher risk in terms of short-term price fluctuations for STIM.Check CARL's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
STIM vs PACB Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, PACB has a market cap of 368.1M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while PACB trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas PACB's P/E ratio is -2.89. In terms of profitability, STIM's ROE is -1.65%, compared to PACB's ROE of -49.62%. Regarding short-term risk, STIM is more volatile compared to PACB. This indicates higher risk in terms of short-term price fluctuations for STIM.Check PACB's competition here
CapsoVision, Inc. (NASDAQ: CV)
STIM vs CV Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, CV has a market cap of 354.7M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while CV trades at $7.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas CV's P/E ratio is -2.84. In terms of profitability, STIM's ROE is -1.65%, compared to CV's ROE of +1.27%. Regarding short-term risk, STIM is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for STIM.Check CV's competition here
Picard Medical, Inc. (AMEX: PMI)
STIM vs PMI Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, PMI has a market cap of 349.2M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while PMI trades at $3.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas PMI's P/E ratio is -2.83. In terms of profitability, STIM's ROE is -1.65%, compared to PMI's ROE of +4.99%. Regarding short-term risk, STIM is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for STIM.Check PMI's competition here
Electromed, Inc. (AMEX: ELMD)
STIM vs ELMD Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, ELMD has a market cap of 348.5M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while ELMD trades at $42.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas ELMD's P/E ratio is 35.97. In terms of profitability, STIM's ROE is -1.65%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, STIM is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for STIM.Check ELMD's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
STIM vs CATX Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, CATX has a market cap of 342.1M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while CATX trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas CATX's P/E ratio is -2.13. In terms of profitability, STIM's ROE is -1.65%, compared to CATX's ROE of -0.42%. Regarding short-term risk, STIM is more volatile compared to CATX. This indicates higher risk in terms of short-term price fluctuations for STIM.Check CATX's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
STIM vs SMLR Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas SMLR's P/E ratio is 3.92. In terms of profitability, STIM's ROE is -1.65%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, STIM is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for STIM.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
STIM vs TMCI Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, TMCI has a market cap of 308.8M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while TMCI trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas TMCI's P/E ratio is -5.06. In terms of profitability, STIM's ROE is -1.65%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, STIM is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for STIM.Check TMCI's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
STIM vs SENS Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, SENS has a market cap of 293.4M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while SENS trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas SENS's P/E ratio is -3.51. In terms of profitability, STIM's ROE is -1.65%, compared to SENS's ROE of -1.66%. Regarding short-term risk, STIM is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for STIM.Check SENS's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
STIM vs ANIK Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, ANIK has a market cap of 286.7M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while ANIK trades at $21.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas ANIK's P/E ratio is 43.71. In terms of profitability, STIM's ROE is -1.65%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, STIM is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for STIM.Check ANIK's competition here
Profound Medical Corp. (NASDAQ: PROF)
STIM vs PROF Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, PROF has a market cap of 269.3M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while PROF trades at $7.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas PROF's P/E ratio is -5.98. In terms of profitability, STIM's ROE is -1.65%, compared to PROF's ROE of -0.56%. Regarding short-term risk, STIM is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for STIM.Check PROF's competition here
RxSight, Inc. (NASDAQ: RXST)
STIM vs RXST Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, RXST has a market cap of 259.1M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while RXST trades at $6.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas RXST's P/E ratio is -6.73. In terms of profitability, STIM's ROE is -1.65%, compared to RXST's ROE of -0.17%. Regarding short-term risk, STIM is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for STIM.Check RXST's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
STIM vs MGRM Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas MGRM's P/E ratio is -12.00. In terms of profitability, STIM's ROE is -1.65%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, STIM is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for STIM.Check MGRM's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
STIM vs FOCL Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, FOCL has a market cap of 233.1M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while FOCL trades at $6.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas FOCL's P/E ratio is -8.00. In terms of profitability, STIM's ROE is -1.65%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, STIM is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for STIM.Check FOCL's competition here
Nevro Corp. (NYSE: NVRO)
STIM vs NVRO Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas NVRO's P/E ratio is -1.91. In terms of profitability, STIM's ROE is -1.65%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, STIM is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for STIM.Check NVRO's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
STIM vs TLSI Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, TLSI has a market cap of 212.7M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while TLSI trades at $5.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas TLSI's P/E ratio is -3.34. In terms of profitability, STIM's ROE is -1.65%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, STIM is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for STIM.Check TLSI's competition here
Avita Medical Inc. (NASDAQ: RCEL)
STIM vs RCEL Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, RCEL has a market cap of 193M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while RCEL trades at $7.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas RCEL's P/E ratio is -4.95. In terms of profitability, STIM's ROE is -1.65%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, STIM is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for STIM.Check RCEL's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
STIM vs BSGM Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas BSGM's P/E ratio is -5.81. In terms of profitability, STIM's ROE is -1.65%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, STIM is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for STIM.Check BSGM's competition here
Quanterix Corporation (NASDAQ: QTRX)
STIM vs QTRX Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, QTRX has a market cap of 189.8M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while QTRX trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas QTRX's P/E ratio is -2.52. In terms of profitability, STIM's ROE is -1.65%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, STIM is more volatile compared to QTRX. This indicates higher risk in terms of short-term price fluctuations for STIM.Check QTRX's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
STIM vs MDGS Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas MDGS's P/E ratio is -0.27. In terms of profitability, STIM's ROE is -1.65%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, STIM is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for STIM.Check MDGS's competition here
Inogen, Inc. (NASDAQ: INGN)
STIM vs INGN Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, INGN has a market cap of 163.8M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while INGN trades at $6.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas INGN's P/E ratio is -6.65. In terms of profitability, STIM's ROE is -1.65%, compared to INGN's ROE of -0.13%. Regarding short-term risk, STIM is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for STIM.Check INGN's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
STIM vs QIPT Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas QIPT's P/E ratio is -15.87. In terms of profitability, STIM's ROE is -1.65%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, STIM is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for STIM.Check QIPT's competition here
iCAD, Inc. (NASDAQ: ICAD)
STIM vs ICAD Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas ICAD's P/E ratio is -20.37. In terms of profitability, STIM's ROE is -1.65%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, STIM is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for STIM.Check ICAD's competition here
Owlet, Inc. (NYSE: OWLT)
STIM vs OWLT Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, OWLT has a market cap of 99.9M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while OWLT trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas OWLT's P/E ratio is -39.43. In terms of profitability, STIM's ROE is -1.65%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, STIM is more volatile compared to OWLT. This indicates higher risk in terms of short-term price fluctuations for STIM.Check OWLT's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
STIM vs LUCD Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, LUCD has a market cap of 98.9M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while LUCD trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas LUCD's P/E ratio is -2.61. In terms of profitability, STIM's ROE is -1.65%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, STIM is more volatile compared to LUCD. This indicates higher risk in terms of short-term price fluctuations for STIM.Check LUCD's competition here
Solana Company (NASDAQ: HSDT)
STIM vs HSDT Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, HSDT has a market cap of 98.7M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while HSDT trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas HSDT's P/E ratio is -0.02. In terms of profitability, STIM's ROE is -1.65%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, STIM is more volatile compared to HSDT. This indicates higher risk in terms of short-term price fluctuations for STIM.Check HSDT's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
STIM vs HJLI Comparison August 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 165.6M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, STIM is priced at $2.38 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -4.41, whereas HJLI's P/E ratio is N/A. In terms of profitability, STIM's ROE is -1.65%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, STIM is more volatile compared to HJLI. This indicates higher risk in terms of short-term price fluctuations for STIM.Check HJLI's competition here